(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
Figure 8: IL-6 neutralizing antibody assays. THP-1 cell-derived macrophages were sequentially treated with 100 ng/ml LPS for 24 h, 2 μg/ml IL-6 neutralizing antibody (anti-IL-6), or IgG isotype control antibody (control-IgG) for 24 h and then cultured with endometrial homogenates or serum from endometriosis patients or control subjects. (a) IL-6 concentration in lysis supernatant of endometrial tissues. After treatment with 100 μl/ml eutopic or ectopic endometrial homogenate for 72 h, the mRNA expression levels of CD163 (b) and IL-10 (c) were detected by RT-PCR. Immunohistochemical staining (d) and quantitative analysis of CD163+ cells (e). (f) Serum IL-6 concentration. After treatment with 10% serum from control subjects versus endometriosis patients for 6 days, the mRNA expression levels of CD163 (g) and IL-10 (h) were detected by RT-PCR. Immunohistochemical staining (i) and quantitative analysis of CD163+ cells (j). LPS: lipopolysaccharide; EMs: endometriosis patients. , , , .